Loading...
KPV
Add to Wishlist
Anti-Inflammatory Tripeptide Studied for Gut and Skin Research
In Stock
Select Size
$50.00$60.00
You Save
$10.00In Stock — Ships Same Day
Includes
5mg research compound
Third-party lab tested
Free shipping on orders over $150
30-day money-back guarantee
Overview
KPV is a C-terminal tripeptide (Lys-Pro-Val) derived from the 13-amino acid alpha-melanocyte-stimulating hormone (alpha-MSH), retaining the parent hormone's potent anti-inflammatory activity despite lacking its melanocortin receptor binding affinity. KPV exerts its effects primarily through direct inhibition of the NF-kB (nuclear factor kappa-light-chain-enhancer of activated B cells) inflammatory signaling cascade, specifically by preventing IkB-alpha phosphorylation and subsequent nuclear translocation of NF-kB p65 subunits. Published research in murine colitis models demonstrated that orally administered KPV significantly reduced intestinal inflammation, decreased pro-inflammatory cytokine levels (TNF-alpha, IL-6, IL-1beta), and improved histological colitis scores, with the peptide being absorbed by colonic epithelial cells through the PepT1 transporter. In dermatological research, KPV has been shown to suppress inflammatory responses in keratinocytes and reduce cutaneous inflammation through melanocortin-independent pathways. What makes KPV unique among anti-inflammatory peptides is its small size (just three amino acids), oral bioactivity in gut tissue, and targeted NF-kB inhibition without broad immunosuppression. Current research explores applications in inflammatory bowel conditions, atopic dermatitis, and systemic inflammatory states.
Handling & Storage
Published research protocols reference subcutaneous and oral administration routes. Store refrigerated at 2-8°C.
Published Research Protocols
Published research protocols reference 200mcg-1mg daily depending on administration route. Consult applicable literature for specific research applications.
Research Applications
NF-kB Inhibition
Directly prevents IkB-alpha phosphorylation and nuclear translocation of NF-kB p65 subunits, suppressing transcription of pro-inflammatory genes including TNF-alpha, IL-6, IL-1beta, and COX-2. This targeted inhibition of the master inflammatory cascade occurs without broad immunosuppressive effects observed with corticosteroids or calcineurin inhibitors.
Initial effects within first month
Research Studies
Gut Inflammation Relief
Orally administered KPV is absorbed by colonic epithelial cells through the PepT1 peptide transporter and exerts local anti-inflammatory effects within the gut mucosa. Published murine colitis research demonstrated significant reductions in histological inflammation scores, decreased neutrophil infiltration, and lower colonic pro-inflammatory cytokine concentrations.
Initial effects within first month
Research Studies
Skin Health
Suppresses inflammatory responses in keratinocytes and reduces cutaneous inflammation through NF-kB-dependent pathways that are independent of classical melanocortin receptor signaling. In vitro research on human skin cells demonstrated reduced IL-8 and TNF-alpha secretion, suggesting potential relevance for inflammatory skin condition research.
Initial effects within first month
Research Studies
Frequently Asked Questions
How is KPV related to alpha-MSH?
KPV (Lys-Pro-Val) is the C-terminal tripeptide fragment of the 13-amino acid alpha-melanocyte-stimulating hormone. It retains the anti-inflammatory activity of the parent hormone through NF-kB inhibition but lacks melanocortin receptor binding, meaning it does not cause skin pigmentation changes. This makes KPV a more targeted anti-inflammatory research tool than full-length alpha-MSH.
Can KPV be used orally in research models?
Yes. Published research demonstrated that KPV is absorbed by colonic epithelial cells through the PepT1 peptide transporter, allowing orally administered KPV to exert local anti-inflammatory effects directly within the intestinal mucosa. This oral bioactivity in gut tissue is unusual for peptides and is a key research advantage of KPV over larger anti-inflammatory molecules.
How should KPV be reconstituted and stored?
Reconstitute lyophilized KPV with bacteriostatic water by slowly injecting along the vial wall. As a very small tripeptide (only 3 amino acids), KPV dissolves rapidly and has good stability in solution. Store unreconstituted peptide at -20°C; after reconstitution, refrigerate at 2-8°C and use within 30 days.
What purity testing does PEPCELL perform on KPV?
Each KPV batch undergoes independent HPLC purity analysis and mass spectrometry identity verification at Janoshik Analytical Laboratory. Current batches test at 99.4% purity, and batch-specific Certificates of Analysis are available for every lot number.
Is KPV intended for human use?
KPV is sold exclusively for in-vitro research, laboratory investigation, and educational purposes. It is not an FDA-approved drug and is not intended for human consumption or self-administration. Research protocols should reference published literature for dosing and administration methodologies.
Important Notice
Not for human consumption. This product is sold exclusively for in-vitro research and laboratory use. It is not a drug, supplement, food item, or cosmetic and has not been evaluated by the FDA.
The research data and clinical references cited on this page are provided for educational reference only and do not constitute medical advice. This product must be handled by qualified research professionals in accordance with all applicable institutional and regulatory guidelines.
Use is restricted to qualified researchers or laboratories operating within appropriate legal and ethical research guidelines. By purchasing, you confirm you are acquiring this product solely for lawful research purposes.
Research Articles
Published research and educational content related to KPV